SGC-CBP30

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

SGC-CBP30 has been used in immunofluorescence, to study the regulation of HAT (histone acetyltransferase) activity. It has also been used to abolish synergistic gene expression induced by transcription factors in hepatocytes.

Biochem/physiol Actions

SGC-CBP30 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC₅₀ = 0.021 and 0.038 µM, respectively). SGC-CBP30 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please visit the SGC-CBP30 probe summary on the Structural Genomics Consortium (SGC) website.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc

SGC-CBP30 might serve as a therapeutic agent in treating cancer. In ankylosing spondylitis and psoriatic arthritis condition, SGC-CBP30 is found to decrease immune cell production of T helper cell 17 and other pro-inflammatory cytokines.

Features and Benefits

SGC-CBP30 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Other Notes

SGC-CBP30 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the SGC-CBP30 probe summary on the Chemical Probes Portal website.

Packaging

5, 25 mg in glass bottle